RYZB
Income statement / Annual
Last year (2022), RayzeBio, Inc. Common Stock's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, RayzeBio, Inc. Common Stock's net income was -$68.60 M.
See RayzeBio, Inc. Common Stock,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$61.18 M
|
$33.88 M
|
$5.84 M
|
| General & Administrative Expenses |
$10.94 M
|
$5.50 M
|
$1.08 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$10.94 M
|
$5.50 M
|
$1.08 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$72.12 M
|
$39.38 M
|
$6.92 M
|
| Cost And Expenses |
$72.12 M
|
$39.38 M
|
$6.92 M
|
| Interest Income |
$3.52 M
|
$265.00 K
|
$5.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.53 M
|
$455.00 K
|
$213.00 K
|
| EBITDA |
-$70.59 M |
-$38.92 M |
-$6.71 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.52 M
|
$9.94 M
|
$5.00 K
|
| Income Before Tax |
-$68.60 M
|
-$29.44 M
|
-$6.92 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$68.60 M
|
-$29.44 M
|
-$6.92 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-1.75 |
-0.73 |
-0.17 |
| EPS Diluted |
-1.75 |
-0.73 |
-0.17 |
| Weighted Average Shares Out |
$39.22 M
|
$40.31 M
|
$40.31 M
|
| Weighted Average Shares Out Diluted |
$39.22 M
|
$40.31 M
|
$40.31 M
|
| Link |
|
|
|
